Novo Nordisk $11b acquisition to support manufacturing capacity
European Pharmaceutical Review
FEBRUARY 5, 2024
Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards. Increasing capacity Acquisition of the three sites will enable the manufacturing capacity to be expanded at scale and speed.
Let's personalize your content